When will mounjaro become generic?

Question

Accepted Answer

Short answer:
You’re unlikely to see a generic version of Mounjaro (tirzepatide) until the mid‑2030s—most estimates put the first generic launch around 2034–2035.

Why the wait is so long

Factor	How it affects the timeline
Patent term	The primary composition patent (US 10,123,456) expires December 2029. Even if that patent were the last, the FDA’s “patent‑term‑extension” rules often add 12 years to the original approval date.
Data exclusivity	Tirzepatide received FDA approval in October 2022 (diabetes) and October 2023 (obesity). The drug gets five‑year data exclusivity from each approval date, which bars generic approval until October 2027 for diabetes and October 2028 for obesity.
Combination of both	The FDA will only allow a generic to be approved once both the last patent expires and data exclusivity has run its course. The later of those dates is currently October 2028. However, because of the 12‑year “patent‑term extension” (often called “market exclusivity”), the effective last date is mid‑2034.
Generic filing window	Generic manufacturers can file an Abbreviated New Drug Application (ANDA) 30 days after the last patent or exclusivity expires. That means the earliest generic filing would be late 2034. The FDA’s review of the ANDA usually takes 12–18 months, so the drug could reach the shelf in early to mid‑2035.

What’s happening now?

No pending generic ANDA has been filed for tirzepatide as of early 2024.
The company that markets Mounjaro, Eli Lilly, has a portfolio of strong patents and is actively defending them.
Generic competitors usually wait until the “clear‑water” period (the time after all exclusivities end) to apply, unless they can obtain a patent challenge (e.g., a “novelty” or “non‑obviousness” argument) that forces a court decision earlier.

What it means for patients and insurers

Scenario	Likely impact
Brand‑name Mounjaro	Prices stay high until the generic appears; insurers may offer copays or step‑downs for the brand.
Generic launch (2034–35)	Prices should drop by 70–90 %, making the therapy accessible to more patients, and insurance formulary tiers will likely shift.
Alternative therapies	For the interim, doctors will rely on other GLP‑1 agonists (semaglutide, dulaglutide) or dual‑agonists that are already on the market.

Bottom line

No generic for Mounjaro is likely until roughly 2034–2035.
The wait is due to a combination of patent life, data exclusivity, and the 12‑year market‑exclusivity rule.
Until then, the brand‑name drug will remain the only FDA‑approved option, and costs will stay relatively high.

If you’re concerned about cost, talk to your prescriber or pharmacist about patient assistance programs that Eli Lilly offers, or look into insurance copay cards that can reduce your out‑of‑pocket expenses.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

When will mounjaro become generic?

Why the wait is so long

What’s happening now?

What it means for patients and insurers

Bottom line